ELQ-300

ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Q_i) site of the cytochrome bc₁ complex (cyt bc₁). ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC₅₀ values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial^[1][2]. IC50 & Target: IC50: 6.6 nM (P. falciparum Dd2), 4.6 nM (P. falciparum Tm90-C2B), 160 nM (P. falciparum D1)^[1] In Vitro: ELQ-300 (0-70 nM, 21 d) inhibits P. falciparum Dd2, Tm90-C2B, and D1 growth with IC₅₀ values of 6.6, 4.6 and 160 nM, respectively^[1]. In Vivo: ELQ-300 (1 and 10 mg/kg; p.o. once daily for 1 or 4 days) inhibits P. yoelii growth in an acute infection model^[2].
ELQ-300 (10 and 20 mg/kg; p.o. once daily for 1 or 4 days) prevents recurrence of infection in mice^[2].